01 9TS-1
02 3UFT
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 68
2019 Revenue in Millions : 89
Growth (%) : -23
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 51
2020 Revenue in Millions : 66
Growth (%) : -17
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 54
2021 Revenue in Millions : 51
Growth (%) : 6
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 53
2022 Revenue in Millions : 54
Growth (%) : 11
Tegafur/Gimeracil/Oteracil Potassium
Main Therapeutic Indication : Oncology
Currency : USD
2024 Revenue in Millions : 47
2023 Revenue in Millions : 53
Growth (%) : -11
Tegafur, Gimeracil, Oteracil Potassium
Main Therapeutic Indication : Oncology
Currency : USD
2016 Revenue in Millions : 243
2015 Revenue in Millions : 261
Growth (%) : -7
Main Therapeutic Indication : Oncology
Currency : USD
2016 Revenue in Millions : 63
2015 Revenue in Millions : 72
Growth (%) : -13
Tegafur, Gimeracil, Oteracil Potassium
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 198
2016 Revenue in Millions : 258
Growth (%) : -23
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 55
2016 Revenue in Millions : 62
Growth (%) : -12
Tegafur, Gimeracil, Oteracil Potassium
Main Therapeutic Indication : Oncology
Currency : USD
2018 Revenue in Millions : 95
2017 Revenue in Millions : 185
Growth (%) : -49%
